Foresite Capital Management VI LLC reported 20 positions worth $616.94M for the quarter ended Jun 30, 2026, up 58.7% on the prior quarter. It opened 7 new positions, added to 6, trimmed 1 and exited 1. Its largest holding is CG Oncology, Inc. at 27.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| SPTX Seaport Therapeutics, Inc. | +1.78M | – | $38.65M | 6.26% |
| PBLS Parabilis Medicines, Inc. | +999.0K | – | $27.34M | 4.43% |
| CLDX Celldex Therapeutics, Inc. | +563.8K | +178.5% | $20.98M | 5.31% |
| GHRS GH Research PLC | +625.0K | +198.1% | $16.80M | 4.1% |
| JBIO Jade Biosciences, Inc. | +566.7K | +177.1% | $12.59M | 3.19% |
| BEAM Beam Therapeutics Inc. | +330.0K | – | $11.33M | 1.84% |
| CGON CG Oncology, Inc. | +148.1K | +6.7% | $10.52M | 27.29% |
| AVBP ArriVent BioPharma, Inc. | +301.3K | – | $10.47M | 1.7% |
| AGIO Agios Pharmaceuticals, Inc. | +260.0K | +49.5% | $9.65M | 4.72% |
| AURA Aura Biosciences, Inc. | +1.33M | – | $9.47M | 1.53% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| SPTX Seaport Therapeutics, Inc. | +1.78M | $38.65M | 6.26% |
| PBLS Parabilis Medicines, Inc. | +999.0K | $27.34M | 4.43% |
| BEAM Beam Therapeutics Inc. | +330.0K | $11.33M | 1.84% |
| AVBP ArriVent BioPharma, Inc. | +301.3K | $10.47M | 1.7% |
| AURA Aura Biosciences, Inc. | +1.33M | $9.47M | 1.53% |
| KLRA Kailera Therapeutics, Inc. | +37.5K | $826.13K | 0.134% |
| IRON Disc Medicine, Inc. | +970 | $70.95K | 0.011% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. | -1.45M | $5.99M | 1.54% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. | Healthcare | 2.37M | $168.36M | 27.29% | +148.1K | +6.7% | Added | 2.68% |
| 2 | ALMS Alumis Inc. | Healthcare | 4.25M | $119.53M | 19.37% | 0 | 0.0% | Unchanged | 3.33% |
| 3 | SPTX Seaport Therapeutics, Inc. | Healthcare | 1.78M | $38.65M | 6.26% | +1.78M | – | New | 3.32% |
| 4 | DNLI Denali Therapeutics Inc. | Healthcare | 1.40M | $35.92M | 5.82% | +186.8K | +15.4% | Added | 0.75% |
| 5 | CLDX Celldex Therapeutics, Inc. | Healthcare | 879.7K | $32.73M | 5.31% | +563.8K | +178.5% | Added | 1.12% |
| 6 | AGIO Agios Pharmaceuticals, Inc. | Healthcare | 785.0K | $29.13M | 4.72% | +260.0K | +49.5% | Added | 1.32% |
| 7 | CRVS Corvus Pharmaceuticals, Inc. | Healthcare | 1.83M | $27.36M | 4.43% | 0 | 0.0% | Unchanged | 1.98% |
| 8 | PBLS Parabilis Medicines, Inc. | Healthcare | 999.0K | $27.34M | 4.43% | +999.0K | – | New | 0.82% |
| 9 | GHRS GH Research PLC | Healthcare | 940.5K | $25.28M | 4.1% | +625.0K | +198.1% | Added | 1.54% |
| 10 | JBIO Jade Biosciences, Inc. | Healthcare | 886.7K | $19.70M | 3.19% | +566.7K | +177.1% | Added | 1.4% |
| 11 | HNGE Hinge Health, Inc. | Healthcare | 220.4K | $18.29M | 2.97% | 0 | 0.0% | Unchanged | 0.35% |
| 12 | KYMR Kymera Therapeutics, Inc. | Healthcare | 146.3K | $16.78M | 2.72% | 0 | 0.0% | Unchanged | 0.15% |
| 13 | VSTM Verastem, Inc. | Healthcare | 3.15M | $12.02M | 1.95% | 0 | 0.0% | Unchanged | 3.14% |
| 14 | BEAM Beam Therapeutics Inc. | Healthcare | 330.0K | $11.33M | 1.84% | +330.0K | – | New | 0.32% |
| 15 | NERV Minerva Neurosciences, Inc. | Healthcare | 1.99M | $11.02M | 1.79% | -1,016 | -0.1% | Reduced | 4.2% |
Tip. Select a row to see that position’s full history at Foresite Capital Management VI.
As of its Q2 2026 13F filing, Foresite Capital Management VI LLC’s five largest positions were CG Oncology, Inc. (CGON) at 27.3%, Alumis Inc. (ALMS) at 19.4%, Seaport Therapeutics, Inc. (SPTX) at 6.3%, Denali Therapeutics Inc. (DNLI) at 5.8%, Celldex Therapeutics, Inc. (CLDX) at 5.3% of the reported portfolio.
Foresite Capital Management VI LLC reported a 13F portfolio worth $616.94M across 20 positions for Q2 2026. That is up 58.7% from the previous quarter.
Its largest purchases by value were Seaport Therapeutics, Inc. ($38.65M), Parabilis Medicines, Inc. ($27.34M), Celldex Therapeutics, Inc. ($20.98M). It opened 7 new positions.
Its largest sales by value were OnKure Therapeutics, Inc. ($5.99M), Minerva Neurosciences, Inc. ($5.64K). It exited 1 positions entirely.
From the Form 13F-HR reports Foresite Capital Management VI LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.